JNJ · JOHNSON & JOHNSON

Back to holdings

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Close · 3M

+22.39%

Held by 3 AI ETFs

PQUS1.200%

as of Sep 1

LQAI0.160%

as of Sep 2

AIEQ0.050%

as of Sep 4

Signal performance

Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.

Buy signals18

Win rate100% (18/18)

Avg buy return+8.57%

PQUSnow 1.200% of fund15 signals

PQUS · Weight decrease · 2d

weight 1.230% → 1.190% (-0.040 pp)·stock up 4.8% in the 30 days before

Aug 29·entry $265.85·now $278.43

+4.73%

since Aug 29

PQUS · Weight increase · 2d

weight 1.170% → 1.230% (+0.060 pp)·stock up 4.6% in the 30 days before

Aug 20·entry $267.37·now $278.43Drifting

+4.14%

since Aug 20

PQUS · Accumulation · 5d

weight 0.850% → 1.200% (+0.350 pp)·stock up 0.9% in the 30 days before

Jul 31·entry $256.35·now $278.43Drifting

+8.61%

since Jul 31

PQUS · Weight increase · 3d

weight 0.850% → 1.170% (+0.320 pp)·stock up 9.3% in the 30 days before

Jul 26·entry $265.95·now $278.43Drifting

+4.69%

since Jul 26

PQUS · Weight increase · 2d

weight 0.850% → 0.890% (+0.040 pp)·stock up 9.3% in the 30 days before

Jul 25·entry $265.95·now $278.43Drifting

+4.69%

since Jul 25

PQUS · Weight increase · 3d

weight 0.820% → 0.860% (+0.040 pp)·stock up 7.6% in the 30 days before

Jul 19·entry $248.82·now $278.43Chased

+11.90%

since Jul 19

PQUS · Weight increase · 2d

weight 0.820% → 0.840% (+0.020 pp)·stock up 7.6% in the 30 days before

Jul 18·entry $248.82·now $278.43Chased

+11.90%

since Jul 18

PQUS · Weight decrease · 3d

weight 0.880% → 0.830% (-0.050 pp)·stock up 8.4% in the 30 days before

Jul 12·entry $257.77·now $278.43

+8.01%

since Jul 12

PQUS · Weight decrease · 2d

weight 0.880% → 0.840% (-0.040 pp)·stock up 8.4% in the 30 days before

Jul 11·entry $257.77·now $278.43

+8.01%

since Jul 11

PQUS · Accumulation · 5d

weight 0.770% → 0.880% (+0.110 pp)·stock up 13.6% in the 30 days before

Jul 1·entry $253.98·now $278.43Drifting

+9.63%

since Jul 1

PQUS · Accumulation · 5d

weight 0.760% → 0.870% (+0.110 pp)·stock up 12.7% in the 30 days before

Jun 30·entry $253.97·now $278.43Drifting

+9.63%

since Jun 30

PQUS · Accumulation · 5d

stock up 12.0% in the 30 days before

Jun 29·entry $258.51·now $278.43Drifting

+7.71%

since Jun 29

PQUS · Accumulation · 5d

stock up 10.1% in the 30 days before

Jun 28·entry $258.51·now $278.43Drifting

+7.71%

since Jun 28

PQUS · Weight increase · 4d

stock up 10.1% in the 30 days before

Jun 27·entry $258.51·now $278.43Drifting

+7.71%

since Jun 27

PQUS · Weight increase · 3d

stock up 10.1% in the 30 days before

Jun 26·entry $254.66·now $278.43Drifting

+9.33%

since Jun 26

LQAInow 0.160% of fund1 signal

LQAI · New entry · 1d

weight 0 → 0.150% (new)·stock down 2.4% in the 30 days before

Aug 6·entry $256.98·now $278.43Drifting

+8.35%

since Aug 6

AIEQnow 0.050% of fund7 signals

AIEQ · Weight decrease · 2d

weight 0.510% → 0.050% (-0.460 pp)·stock up 0.9% in the 30 days before

Aug 2·entry $254.41·now $278.43

+9.44%

since Aug 2

AIEQ · Weight increase · 2d

weight 0.470% → 0.500% (+0.030 pp)·stock up 9.3% in the 30 days before

Jul 24·entry $263.40·now $278.43Drifting

+5.71%

since Jul 24

AIEQ · Weight increase · 2d

weight 0.460% → 0.480% (+0.020 pp)·stock up 7.6% in the 30 days before

Jul 19·entry $248.82·now $278.43Chased

+11.90%

since Jul 19

AIEQ · Weight decrease · 2d

weight 0.490% → 0.460% (-0.030 pp)·stock up 6.1% in the 30 days before

Jul 16·entry $249.97·now $278.43

+11.39%

since Jul 16

AIEQ · Accumulation · 5d

stock up 10.1% in the 30 days before

Jun 28·entry $258.51·now $278.43Drifting

+7.71%

since Jun 28

AIEQ · Weight increase · 3d

stock up 10.1% in the 30 days before

Jun 26·entry $254.66·now $278.43Drifting

+9.33%

since Jun 26

AIEQ · Weight increase · 2d

stock up 6.4% in the 30 days before

Jun 25·entry $244.88·now $278.43Chased

+13.70%

since Jun 25

Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.

Buffett-style framework

Fails the frameworkas of Aug 30

AI ETFs like QRFT, PQUS, LQAI, and AIEQ currently hold Johnson & Johnson, suggesting a positive view by their algorithms, with PQUS showing recent minor adjustments in weight. This stance contrasts with a Buffett-style "Fail" verdict, which is primarily driven by the absence of a margin of safety at JNJ's current market valuation, suggesting the price paid may not reflect a conservative estimate of intrinsic value. While the company exhibits strong fundamental qualities, its price negates a conservative investment opportunity for a value investor.

Circle of CompetenceIts diversified nature across pharmaceuticals, medical devices, and consumer health provides a stable and predictable demand profile, allowing for reasonable long-term cash flow projections despite industry-specific complexities.
Economic MoatJNJ possesses a strong economic moat derived from its extensive portfolio of patented pharmaceuticals, high brand recognition in consumer health, significant switching costs in medical devices, and vast scale in R&D and distribution.
ManagementInformation regarding management's candor, specific capital allocation decisions, and "skin in the game" is not available from the provided financial snapshots.
Financial HealthThe provided financials (ROE: 25.74%) do not offer a 10-year average ROE, historical operating margins, detailed debt structure, or owner earnings, preventing a full assessment against all specified criteria.
Margin of SafetyThe current valuation multiples (PER 29.93, PBR 6.13, EV/EBITDA 30.15) suggest the company is trading at a premium, leaving no apparent margin of safety.

Johnson & Johnson presents as a high-quality business with a predictable earning stream and robust economic moats, aligning well with the initial stages of a value investing framework. However, due to insufficient data for a complete management and financial health assessment, and crucially, the absence of a margin of safety at its current valuation, the overall verdict is a "Fail". This indicates that while it's a wonderful company, its present price makes it a less attractive investment through this specific lens.

Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.